CN112279914A - IL4RA antibodies, genes, vectors, host cells and IL4RA antagonists - Google Patents
IL4RA antibodies, genes, vectors, host cells and IL4RA antagonists Download PDFInfo
- Publication number
- CN112279914A CN112279914A CN201910676472.1A CN201910676472A CN112279914A CN 112279914 A CN112279914 A CN 112279914A CN 201910676472 A CN201910676472 A CN 201910676472A CN 112279914 A CN112279914 A CN 112279914A
- Authority
- CN
- China
- Prior art keywords
- il4ra
- seq
- antibody
- sequence shown
- gly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention relates to the technical field of antibodies, in particular to an IL4RA antibody, a gene, a vector, a host cell and an IL4RA antagonist. The heavy chain of the IL4RA antibody comprises SEQ ID NO: 1, CDR1 of the sequence shown in SEQ ID NO: 2, CDR2 of the sequence shown in SEQ ID NO: 3 CDR3 of the sequence shown in seq id no; the light chain of IL4RA antibody comprises SEQ ID NO: 4, CDR4 of the sequence shown in SEQ ID NO: 5, CDR5 of the sequence shown in SEQ ID NO: 6, CDR6 of the sequence shown in seq id no. The IL4RA antibody of the invention can be specifically combined with cell surface hIL4RA, and can be used as an antagonist of IL4RA signal transduction, so the antibody can be used for treating IL4RA related diseases, such as asthma.
Description
Technical Field
The invention relates to the technical field of antibodies, in particular to an IL4RA antibody, a gene, a vector, a host cell and an IL4RA antagonist.
Background
IL-4 (also known as B cell stimulating factor or BSF-1) has a wide range of biological functions that can stimulate the activation of T cells, mast cells, granulocytes and megakaryocytes, while inducing expression of MHC-II in resting B cells and enhancing IgE secretion by stimulating B cells (Reddy et al (2000) J.Immunol.164: 1925-.
Asthma is a chronic inflammatory allergic disease of respiratory tract, the incidence rate of the asthma is high, and no medicament with particularly good curative effect exists at present. It is well known that IL-4 is a Th2 type cytokine, the biological activity of which is mediated by its specific cell surface IL-4 receptor. IL-4 is a cytokine secreted by Th2 cells, which plays an important role with IL-13 in the development of allergic asthma (Zura Wski G.et al, Immunol.today, Vol.15:19-26 (1994)). The two cytokines, IL-13 and IL-4, share significant structural similarities in cells, and share certain receptor components while having separate receptors. Such as IL-4 and IL-13 dual receptors IL-4R/IL-13Ra1, the receptor contains IL-4Ra chain and IL-13Ra1 chain, its main expression in hematopoietic and non-hematopoietic cells, including lung epithelial and smooth muscle cells. In addition, IL-4 and IL-13 each have a receptor that recognizes themselves but not the other. The type I receptor IL-4R, such as IL-4, comprises an IL-4Ra chain and a common gamma chain, which specifically bind IL-4, and the type I receptor IL-4R for IL-4 is exclusively expressed on cells of hematopoietic origin. The receptor specific for IL-13 is IL-13Ra2, which has a specific high affinity for IL-13, but which is not capable of downstream signaling (Caput D.et al, J.biol.Chern., Vol.271: 16965 (1996)). Antagonists of IL4RA signaling would therefore be useful in the treatment of IL4RA related diseases, such as asthma.
Disclosure of Invention
In view of the above, the present invention provides IL4RA antibodies, genes, vectors, host cells and IL4RA antagonists. The IL4RA antibody can be specifically combined with cell surface hIL4RA, and can be used as IL4RA signaling antagonist.
In order to achieve the above object, the present invention provides the following technical solutions:
the invention provides an IL4RA antibody, the heavy chain of which IL4RA antibody comprises SEQ ID NO: 1, CDR1 of the sequence shown in SEQ ID NO: 2, CDR2 of the sequence shown in SEQ ID NO: 3 CDR3 of the sequence shown in seq id no;
the light chain of IL4RA antibody comprises SEQ ID NO: 4, CDR4 of the sequence shown in SEQ ID NO: 5, CDR5 of the sequence shown in SEQ ID NO: 6, CDR6 of the sequence shown in seq id no.
In the invention, the heavy chain and the light chain of the IL4RA antibody are connected by a linker, and the amino acid sequence of the linker is shown as SEQ ID NO: shown at 7.
The invention also provides an IL4RA antibody, wherein the amino acid sequence of the IL4RA antibody is shown in SEQ ID NO: shown in fig. 8.
Preferably, the IL4RA antibody is a humanized antibody.
The invention also provides a gene for coding the IL4RA antibody, and the base sequence of the gene is shown as SEQ ID NO: shown at 9.
The invention also provides a vector comprising a gene encoding an IL4RA antibody.
Preferably, the plasmid used for the vector is pcDNA 4/myc-HisA.
The invention also provides a host cell comprising the vector.
Preferably, the host cell is a HEK293 cell.
The invention also provides a preparation method of the IL4RA antibody, which comprises the following steps: after fusion of scFv gene (shown in SEQ ID NO: 9) and IgG1-Fc gene, the single-chain antibody was cloned into vector pcDNA4/myc-HisA by HindIII and EcoRI double digestion, cloning and plasmid miniextraction were carried out, the extracted plasmid was expressed in HEK293 cells and purified by protein A column.
The invention also provides an IL4RA antagonist, including the IL4RA antibody provided by the invention.
The invention provides IL4RA antibodies, genes, vectors, host cells and IL4RA antagonists. The heavy chain of the IL4RA antibody comprises SEQ ID NO: 1, CDR1 of the sequence shown in SEQ ID NO: 2, CDR2 of the sequence shown in SEQ ID NO: 3 CDR3 of the sequence shown in seq id no; the light chain of IL4RA antibody comprises SEQ ID NO: 4, CDR4 of the sequence shown in SEQ ID NO: 5, CDR5 of the sequence shown in SEQ ID NO: 6, CDR6 of the sequence shown in seq id no. The invention has the technical effects that:
the IL4RA antibody of the invention can be specifically combined with cell surface hIL4RA, and can be used as an antagonist of IL4RA signal transduction, so the antibody can be used for treating IL4RA related diseases, such as asthma.
Drawings
FIG. 1 shows the characterization results of anti-IL4RA antibody, where 1-1 is blank control, 1-2 is negative control, and 1-3 is flow cytometry diagram of the combination of anti-hIL4RA scFv antibody and cell surface hIL4 RA.
Detailed Description
IL4RA antibodies, genes, vectors, host cells and IL4RA antagonists are disclosed and can be achieved by one skilled in the art with appropriate modification of the process parameters in view of the disclosure herein. It is expressly intended that all such similar substitutes and modifications which would be obvious to one skilled in the art are deemed to be included in the invention. While the methods and applications of this invention have been described in terms of preferred embodiments, it will be apparent to those of ordinary skill in the art that variations and modifications in the methods and applications described herein, as well as other suitable variations and combinations, may be made to implement and use the techniques of this invention without departing from the spirit and scope of the invention.
Reagents, instruments or materials used in the IL4RA antibodies, genes, vectors, host cells and IL4RA antagonists provided by the invention are commercially available.
The invention is further illustrated by the following examples:
example 1: expression of recombinant human IL4RA and EGFP cell preparation
Obtaining the amino acid sequence of the extracellular domain of human IL-4RA (i.e. residues 1 to 232 in P24394) according to the amino acid sequence of human IL-4RA on Uniprot (P24394) of a protein database; the amino acid sequence of IL4RA is as follows (wherein the underlined part is the extracellular domain):
MGWLCSGLLFPVSCLVLLQVASSGNMKVLQEPTCVSDYMSISTCEWKMNGPTNCSTELRLLYQLVFLLS EAHTCIPENNGGAGCVCHLLMDDVVSADNYTLDLWAGQQLLWKGSFKPSEHVKPRAPGNLTVHTNVSDTLLLTWSNP YPPDNYLYNHLTYAVNIWSENDPADFRIYNVTYLEPSLRIAASTLKSGISYRARVRAWAQCYNTTWSEWSPSTKWHN SYREPFEQHLLLGVSVSCIVILAVCLLCYVSITKIKKEWWDQIPNPARSRLVAIIIQDAQGSQWEKRSRGQEPAKCPHWKNCLTKLLPCFLEHNMKRDEDPHKAAKEMPFQGSGKSAWCPVEISKTVLWPESISVVRCVELFEAPVECEEEEEVEEEKGSFCASPESSRDDFQEGREGIVARLTESLFLDLLGEENGGFCQQDMGESCLLPPSGSTSAHMPWDEFPSAGPKEAPPWGKEQPLHLEPSPPASPTQSPDNLTCTETPLVIAGNPAYRSFSNSLSQSPCPRELGPDPLLARHLEEVEPEMPCVPQLSEPTTVPQPEPETWEQILRRNVLQHGAAAAPVSAPTSGYQEFVHAVEQGGTQASAVVGLGPPGEAGYKAFSSLLASSAVSPEKCGFGASSGEEGYKPFQDLIPGCPGDPAPVPVPLFTFGLDREPPRSPQSSHLPSSSPEHLGLEPGEKVEDMPKPPLPQEQATDPLVDSLGSGIVYSALTCHLCGHLKQCHGQEDGGQTPVMASPCCGCCCGDRSSPPTTPLRAPDPSPGGVPLEASLCPASLAPSGISEKSKSSSSFHPAPGNAQSSSQTPKIVNFVSVGPTYMRVS
the base sequence is as follows:
atggggtggctttgctctgggctcctgttccctgtgagctgcctggtcctgctgcaggtggcaagctc tgggaacatgaaggtcttgcaggagcccacctgcgtctccgactacatgagcatctctacttgcgagtggaagatg aatggtcccaccaattgcagcaccgagctccgcctgttgtaccagctggtttttctgctctccgaagcccacacgt gtatccctgagaacaacggaggcgcggggtgcgtgtgccacctgctcatggatgacgtggtcagtgcggataacta tacactggacctgtgggctgggcagcagctgctgtggaagggctccttcaagcccagcgagcatgtgaaacccagg gccccaggaaacctgacagttcacaccaatgtctccgacactctgctgctgacctggagcaacccgtatccccctg acaattacctgtataatcatctcacctatgcagtcaacatttggagtgaaaacgacccggcagatttcagaatcta taacgtgacctacctagaaccctccctccgcatcgcagccagcaccctgaagtctgggatttcctacagggcacgg gtgagggcctgggctcagtgctataacaccacctggagtgagtggagccccagcaccaagtggcacaactcctaca gggagcccttcgagcagcacctcctgctgggcgtcagcgtttcctgcattgtcatcctggccgtctgcctgttgtgctatgtcagcatcaccaagattaagaaagaatggtgggatcagattcccaacccagcccgcagccgcctcgtggctataataatccaggatgctcaggggtcacagtgggagaagcggtcccgaggccaggaaccagccaagtgcccacactggaagaattgtcttaccaagctcttgccctgttttctggagcacaacatgaaaagggatgaagatcctcacaaggctgccaaagagatgcctttccagggctctggaaaatcagcatggtgcccagtggagatcagcaagacagtcctctggccagagagcatcagcgtggtgcgatgtgtggagttgtttgaggccccggtggagtgtgaggaggaggaggaggtagaggaagaaaaagggagcttctgtgcatcgcctgagagcagcagggatgacttccaggagggaagggagggcattgtggcccggctaacagagagcctgttcctggacctgctcggagaggagaatgggggcttttgccagcaggacatgggggagtcatgccttcttccaccttcgggaagtacgagtgctcacatgccctgggatgagttcccaagtgcagggcccaaggaggcacctccctggggcaaggagcagcctctccacctggagccaagtcctcctgccagcccgacccagagtccagacaacctgacttgcacagagacgcccctcgtcatcgcaggcaaccctgcttaccgcagcttcagcaactccctgagccagtcaccgtgtcccagagagctgggtccagacccactgctggccagacacctggaggaagtagaacccgagatgccctgtgtcccccagctctctgagccaaccactgtgccccaacctgagccagaaacctgggagcagatcctccgccgaaatgtcctccagcatggggcagctgcagcccccgtctcggcccccaccagtggctatcaggagtttgtacatgcggtggagcagggtggcacccaggccagtgcggtggtgggcttgggtcccccaggagaggctggttacaaggccttctcaagcctgcttgccagcagtgctgtgtccccagagaaatgtgggtttggggctagcagtggggaagaggggtataagcctttccaagacctcattcctggctgccctggggaccctgccccagtccctgtccccttgttcacctttggactggacagggagccacctcgcagtccgcagagctcacatctcccaagcagctccccagagcacctgggtctggagccgggggaaaaggtagaggacatgccaaagcccccacttccccaggagcaggccacagacccccttgtggacagcctgggcagtggcattgtctactcagcccttacctgccacctgtgcggccacctgaaacagtgtcatggccaggaggatggtggccagacccctgtcatggccagtccttgctgtggctgctgctgtggagacaggtcctcgccccctacaacccccctgagggccccagacccctctccaggtggggttccactggaggccagtctgtgtccggcctccctggcaccctcgggcatctcagagaagagtaaatcctcatcatccttccatcctgcccctggcaatgctcagagctcaagccagacccccaaaatcgtgaactttgtctccgtgggacccacatacatgagggtctcttag
the amino acid sequence of the domain of human IgG1-Fc (i.e., residues 104 to 330 in P01857) was obtained from the amino acid sequence of the constant region of human immunoglobulin gamma (gamma) 1(IgG1) on Unit protein database (P01857). The IgG1-Fc amino acid sequence is as follows:
DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
the base sequence is as follows:
gacaaaactcacacatgcccaccgtgcccagctccggaactcctgggcggaccgtcagtcttcctcttccccccaaaacccaaggacaccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaaccatctccaaagccaaagggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcctgacctgcctggtcaaaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacgcctcccgtgttggactccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaa
the gene of hIL4RA-Fc fusion protein is obtained by designing a corresponding coding DNA sequence by using a DNAworks online tool (http:// helix web. nih. gov/DNAworks /).
Obtaining an enhanced green fluorescent protein EGFP amino acid sequence (C5MKY7) and an amino acid sequence (P24394) of human IL4RA according to information on a protein database Unit, wherein the EGFP amino acid sequence is as follows: MVSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTLTYGVQCFSRYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMADKQKNGIKVNFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKRDHMVLLEFVTAAGITLGMDELYK
The base sequence is as follows:
atggtgagcaagggcgaggagctgttcaccggggtggtgcccatcctggtcgagctggacggcgacgtaaacggccacaagttcagcgtgtccggcgagggcgagggcgatgccacctacggcaagctgaccctgaagttcatctgcaccaccggcaagctgcccgtgccctggcccaccctcgtgaccaccctgacctacggcgtgcagtgcttcagccgctaccccgaccacatgaagcagcacgacttcttcaagtccgccatgcccgaaggctacgtccaggagcgcaccatcttcttcaaggacgacggcaactacaagacccgcgccgaggtgaagttcgagggcgacaccctggtgaaccgcatcgagctgaagggcatcgacttcaaggaggacggcaacatcctggggcacaagctggagtacaactacaacagccacaacgtctatatcatggccgacaagcagaagaacggcatcaaggtgaacttcaagatccgccacaacatcgaggacggcagcgtgcagctcgccgaccactaccagcagaacacccccatcggcgacggccccgtgctgctgcccgacaaccactacctgagcacccagtccgccctgagcaaagaccccaacgagaagcgcgatcacatggtcctgctggagttcgtgaccgccgccgggatcactctcggcatggacgagctgtacaag
a DNAworks online tool (http:// helix web. nih. gov/DNAworks /) is used for designing a corresponding coding DNA sequence to obtain a gene of the hIL4RA and EGFP fusion protein, and a gene of hIL4 RA-EGFP. The DNA fragment is obtained by artificial synthesis. The synthesized gene sequence is subcloned into a commercial vector pcDNA4/myc-HisA (Invitrogen, V863-20) through HindIII and EcoRI double enzyme digestion of Fermentas company, and the accuracy of the constructed plasmid is verified by sequencing to obtain recombinant plasmid DNA, namely: pcDNA4-hIL4RA-Fc and pcDNA4-hIL4 RA-EGFP.
The relevant EGFP recombinant plasmid was transfected into HEK293(ATCC, CRL-1573)TM) In cells, expression of hIL4RA was confirmed 48h after transfection by fluorescence activated signal sorting (FACS).
pcDNA4-hIL4RA-Fc was transiently transfected into HEK293 cells for protein production. Diluting the recombinant expression plasmid with Freestyle293 medium and adding PEI (polyethyleneimine) solution required for transformation, adding each group of plasmid/PEI mixture into the cell suspension respectively, and placing at 37 ℃ and 10% CO2Culturing at 90 rpm; after 5-6 days of culture, transient expression culture supernatant was collected and subjected to primary purification by protein affinity chromatography to obtain a hIL4RA-Fc protein sample, which was used in the following examples. The obtained protein sample is subjected to primary detection by SDS-PAGE, and a target band can be clearly seen.
Example 2: screening anti-IL4RA antibody from yeast display library, cloning and expressing
The yeast display technology is adopted to screen the whole human antibody of the human IL4 RA. Construction of scFV yeast display library by cloning VH and VL genes in IgM and IgG cDNAs from PBMCs of 50 healthy humans (the linker sequence between VH and VL is GILGSGGGGSGGGGSGGGGS linker peptide, the library content is 5X 108. Recovering the yeast library with 10 times of library volume, inducing yeast surface expression antibody, and using 100nM biotinylated hIL4RA-Fc antigenEnrichment was done twice using magnetic bead sorting and then twice again using biotinylated hIL4RA-Fc as flow sort. The resulting yeast was plated and single clones were picked. After amplification and induction of expression, the monoclonal yeast were analyzed by biotinylated hIL4RA-Fc staining to identify positive yeast. Yeast clones confirmed by FACS were subjected to yeast colony PCR and sequencing with PCR primers:
sequence-F:CGTAGAATCGAGACCGAGGAGA;
sequence-R:CTGGTGGTGGTGGTTCTGCTAGC;
the sequencing primer is sequence-R. And after a sequencing result is obtained, the sequences are compared and analyzed by using BioEdit software.
The scFv gene of the single-chain antibody obtained above and the human IgG1-Fc gene were fused and cloned into a commercial vector pcDNA4/myc-HisA by means of double digestion with HindIII and EcoRI from Fermentas corporation, and cloning and plasmid extraction were carried out according to standard procedures for molecular cloning. The extracted plasmid was transiently expressed in HEK293 cells and purified by protein a column. The amino acid sequence of the anti-hIL4RAscFv antibody is shown in SEQ ID NO: 8 (VH-Linker-VL, CDR in the wavy line portion and Linker in the underline):
QVQLVESEAEVRKPGASVKVSCKASGYTFTWVRQAPGQGLEWMGRVTMTRDTSTSIDYMELSSLRFEDTAVYYCVR WGQGTLVTVSSGILGSGGGGSGGGGSGGGGSQSVLIQPASVSGSPGQSITISCWYQQHPGKAPKLMIY GVPDRFSGSKSGNTASLTISGLQPEDEADYYCFGGGTKVTVL
the base sequence is shown as SEQ ID NO: 9 is as follows:
caggtgcagcttgtggagtctgaggctgaggtgaggaagcctggggcctcagtgaaggtttcctgcaaggcatctggatacaccttcaccacctactatatgaactgggtgcgacaggcccctggacaagggcttgagtggatgggaataatcagccctaggggtgacaggactgtctacgcaccgaagttccagggcagagtcaccatgaccagggacacgtccacgagtatagattacatggaactgagcagcctgagatttgaggacacggccgtgtattactgtgtgagaggtgatactggtaaccggataaagggagagtttgacctttggggccagggaaccctggtcaccgtctcctcaggaattctaggatccggtggcggtggcagcggcggtggtggttccggaggcggcggttctcagtctgttctgattcagcctgcctccgtgtctgggtctcctggacagtcgatcaccatctcctgcactggaacgagcggtgacgttggtggttataactatgtctcctggtaccaacagcacccaggcaaagcccccaaactcatgatttatgaggtcagtaagcggccctcaggggtccctgatcgcttctctggctccaagtcgggaaacacggcctccctgaccatctctgggctgcagcctgaggacgaggctgattattactgcttctcctacagacatactattagttctttcgtcttcggcggagggaccaaggtcaccgtccta
example 3: characterization of anti-IL4R antibodies (characterization by binding to IL 4R-FACS method)
Taking hIL4RA-EGFP cells, suspending the cells in 0.5% PBS-BSABuffer, adding 2 μ g of anti-hIL4RAscFv antibody after purification, and setting a relevant control at the same time, wherein the negative control is 2 μ g of hIgG1 protein. The secondary antibody is anti-hIg-PE of eBioscience. And detecting by a flow cytometer after dyeing. Antibodies that bind cell surface hIL4RA antigen were identified in this manner. As shown in FIG. 1, anti-IL4RA11# can bind to cell surface hIL4RA, while the negative control is unable to bind to cell surface hIL4 RA.
The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and decorations can be made without departing from the principle of the present invention, and these modifications and decorations should also be regarded as the protection scope of the present invention.
Sequence listing
<110> Suzhou Dingfu target biotech Co., Ltd
<120> IL4RA antibodies, genes, vectors, host cells and IL4RA antagonists
<130> MP1917792
<160> 9
<170> SIPOSequenceListing 1.0
<210> 1
<211> 5
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 1
Thr Tyr Tyr Met Asn
1 5
<210> 2
<211> 17
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 2
Ile Ile Ser Pro Arg Gly Asp Arg Thr Val Tyr Ala Pro Lys Phe Gln
1 5 10 15
Gly
<210> 3
<211> 13
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 3
Gly Asp Thr Gly Asn Arg Ile Lys Gly Glu Phe Asp Leu
1 5 10
<210> 4
<211> 14
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 4
Thr Gly Thr Ser Gly Asp Val Gly Gly Tyr Asn Tyr Val Ser
1 5 10
<210> 5
<211> 7
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 5
Glu Val Ser Lys Arg Pro Ser
1 5
<210> 6
<211> 11
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 6
Phe Ser Tyr Arg His Thr Ile Ser Ser Phe Val
1 5 10
<210> 7
<211> 20
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 7
Gly Ile Leu Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
1 5 10 15
Gly Gly Gly Ser
20
<210> 8
<211> 253
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 8
Gln Val Gln Leu Val Glu Ser Glu Ala Glu Val Arg Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr
20 25 30
Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Ile Ile Ser Pro Arg Gly Asp Arg Thr Val Tyr Ala Pro Lys Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Ile Asp Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Phe Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Val Arg Gly Asp Thr Gly Asn Arg Ile Lys Gly Glu Phe Asp Leu Trp
100 105 110
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Ile Leu Gly Ser Gly
115 120 125
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Ser
130 135 140
Val Leu Ile Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile
145 150 155 160
Thr Ile Ser Cys Thr Gly Thr Ser Gly Asp Val Gly Gly Tyr Asn Tyr
165 170 175
Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile
180 185 190
Tyr Glu Val Ser Lys Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly
195 200 205
Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Pro
210 215 220
Glu Asp Glu Ala Asp Tyr Tyr Cys Phe Ser Tyr Arg His Thr Ile Ser
225 230 235 240
Ser Phe Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu
245 250
<210> 9
<211> 759
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 9
caggtgcagc ttgtggagtc tgaggctgag gtgaggaagc ctggggcctc agtgaaggtt 60
tcctgcaagg catctggata caccttcacc acctactata tgaactgggt gcgacaggcc 120
cctggacaag ggcttgagtg gatgggaata atcagcccta ggggtgacag gactgtctac 180
gcaccgaagt tccagggcag agtcaccatg accagggaca cgtccacgag tatagattac 240
atggaactga gcagcctgag atttgaggac acggccgtgt attactgtgt gagaggtgat 300
actggtaacc ggataaaggg agagtttgac ctttggggcc agggaaccct ggtcaccgtc 360
tcctcaggaa ttctaggatc cggtggcggt ggcagcggcg gtggtggttc cggaggcggc 420
ggttctcagt ctgttctgat tcagcctgcc tccgtgtctg ggtctcctgg acagtcgatc 480
accatctcct gcactggaac gagcggtgac gttggtggtt ataactatgt ctcctggtac 540
caacagcacc caggcaaagc ccccaaactc atgatttatg aggtcagtaa gcggccctca 600
ggggtccctg atcgcttctc tggctccaag tcgggaaaca cggcctccct gaccatctct 660
gggctgcagc ctgaggacga ggctgattat tactgcttct cctacagaca tactattagt 720
tctttcgtct tcggcggagg gaccaaggtc accgtccta 759
Claims (10)
1. An IL4RA antibody, wherein the heavy chain of the IL4RA antibody comprises the amino acid sequence of SEQ ID NO: 1, CDR1 of the sequence shown in SEQ ID NO: 2, CDR2 of the sequence shown in SEQ ID NO: 3 CDR3 of the sequence shown in seq id no;
the light chain of the IL4RA antibody comprises SEQ ID NO: 4, CDR4 of the sequence shown in SEQ ID NO: 5, CDR5 of the sequence shown in SEQ ID NO: 6, CDR6 of the sequence shown in seq id no.
2. The IL4RA antibody of claim 1, wherein the heavy chain and the light chain of the IL4RA antibody are linked by a linker having an amino acid sequence as set forth in SEQ ID NO: shown at 7.
3. An IL4RA antibody, wherein the amino acid sequence of the IL4RA antibody is as set forth in SEQ ID NO: shown in fig. 8.
4. The IL4RA antibody according to claim 3, characterized in that the IL4RA antibody is a humanized antibody.
5. A gene encoding the IL4RA antibody of claim 3 or 4, characterized in that the base sequence is as set forth in SEQ ID NO: shown at 9.
6. A vector comprising the gene of claim 5.
7. The vector of claim 6, wherein the plasmid used in the vector is pcDNA 4/myc-HisA.
8. A host cell comprising the vector of claim 6.
9. The host cell of claim 8, wherein the host cell is a HEK293 cell.
10. An IL4RA antagonist, comprising the IL4RA antibody of any one of claims 1 to 4.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910676472.1A CN112279914A (en) | 2019-07-25 | 2019-07-25 | IL4RA antibodies, genes, vectors, host cells and IL4RA antagonists |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910676472.1A CN112279914A (en) | 2019-07-25 | 2019-07-25 | IL4RA antibodies, genes, vectors, host cells and IL4RA antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112279914A true CN112279914A (en) | 2021-01-29 |
Family
ID=74419439
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910676472.1A Pending CN112279914A (en) | 2019-07-25 | 2019-07-25 | IL4RA antibodies, genes, vectors, host cells and IL4RA antagonists |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112279914A (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101522716A (en) * | 2006-10-02 | 2009-09-02 | 瑞泽恩制药公司 | High affinity human antibodies to human IL-4 receptor |
CN105777906A (en) * | 2014-12-19 | 2016-07-20 | 苏州丁孚靶点生物技术有限公司 | Anti-PD - L1 human antibody and application thereof |
CN108026169A (en) * | 2015-09-22 | 2018-05-11 | 苏州丁孚靶点生物技术有限公司 | The fully human antibodies of anti-human CD137 and its application |
CN108137684A (en) * | 2015-10-15 | 2018-06-08 | 苏州丁孚靶点生物技术有限公司 | Anti- OX40 antibody and its application |
CN108373505A (en) * | 2018-04-20 | 2018-08-07 | 北京智仁美博生物科技有限公司 | Anti- IL-4R antibody and application thereof |
-
2019
- 2019-07-25 CN CN201910676472.1A patent/CN112279914A/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101522716A (en) * | 2006-10-02 | 2009-09-02 | 瑞泽恩制药公司 | High affinity human antibodies to human IL-4 receptor |
CN105777906A (en) * | 2014-12-19 | 2016-07-20 | 苏州丁孚靶点生物技术有限公司 | Anti-PD - L1 human antibody and application thereof |
CN108026169A (en) * | 2015-09-22 | 2018-05-11 | 苏州丁孚靶点生物技术有限公司 | The fully human antibodies of anti-human CD137 and its application |
CN108137684A (en) * | 2015-10-15 | 2018-06-08 | 苏州丁孚靶点生物技术有限公司 | Anti- OX40 antibody and its application |
CN108373505A (en) * | 2018-04-20 | 2018-08-07 | 北京智仁美博生物科技有限公司 | Anti- IL-4R antibody and application thereof |
Non-Patent Citations (1)
Title |
---|
姚文兵主编: "蛋白质分子的展示及筛选技术", 《生物技术制药概论》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113214398B (en) | Fully human antibodies against human CD137 and uses thereof | |
CN110746507B (en) | human interleukin 4 receptor α monoclonal antibody and its application | |
CN107880128B (en) | Fully human antibody or antibody fragment for resisting CD19, and method and application thereof | |
CN108251431B (en) | Double-carrier system and application thereof | |
CN110964111B (en) | anti-PD-L1 monoclonal antibody, antigen binding fragment thereof and application thereof | |
CN111040035B (en) | Antibody aiming at IL-17RA protein and preparation method and application thereof | |
CN110156895B (en) | anti-PD-L1 antibody or functional fragment thereof and application thereof | |
CN114621345A (en) | anti-LAG-3 monoclonal antibody, antigen binding fragment thereof and application thereof | |
CN113527493A (en) | B7-H3 antibody and application thereof | |
Butler et al. | Engineering a natural ligand-based CAR: directed evolution of the stress-receptor NKp30 | |
CN117050195B (en) | Targeting BAFFR chimeric antigen receptor, CAR-T cell and application | |
CN117700554B (en) | Anti-humanized CD132 monoclonal antibody and application thereof | |
CN110903393B (en) | Polypeptide capable of binding IL6R alpha and application thereof | |
CN112279914A (en) | IL4RA antibodies, genes, vectors, host cells and IL4RA antagonists | |
US20240150460A1 (en) | Anti-nkp30 antibody and application thereof | |
CN112279916A (en) | IL13RA1 antibodies, genes, vectors, host cells and IL13RA1 antagonists | |
CN113896793A (en) | Anti-human IL-17RC monoclonal antibody and application thereof | |
CN111699006B (en) | IL17 antibodies and uses thereof | |
CN112300277A (en) | CSF1R antibodies, genes, vectors, host cells and CSF1R antagonists | |
CN112279915A (en) | ICOS antibodies, genes, vectors, host cells and ICOS antagonists | |
WO2023217072A1 (en) | Therapeutic agent comprising multispecific antibody and use thereof in tumor therapy | |
WO2024131970A1 (en) | Cell composition, and use and drug thereof | |
RU2811518C1 (en) | Il-5 binding molecule, method of its preparation and its use | |
WO2024152962A1 (en) | Anti-tt3 humanized antibody and use thereof | |
CN113150155A (en) | anti-PD-L1 humanized monoclonal antibody and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210129 |